Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily Healthcare Bull 3X ETF

124.02
-0.0200-0.02%
Post-market: 124.020.00000.00%19:33 EDT
Volume:27.12K
Turnover:3.35M
Market Cap:155.03M
PE:- -
High:124.88
Open:124.88
Low:121.95
Close:124.04
52wk High:150.00
52wk Low:82.41
Shares:1.25M
Float Shares:1.25M
Volume Ratio:0.53
T/O Rate:2.17%
Dividend:1.27
Dividend Rate:1.02%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly & Co (LLY) Gets a Buy from RBC Capital

TIPRANKS
·
Yesterday

Former Eli Lilly Exec Sells Wyoming Estate for Close to $39.5 Million

Dow Jones
·
Yesterday

Eli Lilly announces FDA approves additional indication for Jaypirca

TIPRANKS
·
Yesterday

Lilly Says FDA Approves Expanded First-Line Cll/sll Use for Jaypirca

Reuters
·
Yesterday

Lilly's Jaypirca (Pirtobrutinib), the First-and-Only Approved Non-Covalent Btk Inhibitor, Receives Expanded Indication from U.S. FDA for Certain Patients with Previously Untreated Cll/Sll

THOMSON REUTERS
·
Yesterday

Correction: Top Midday Decliners

MT Newswires Live
·
Oct 02

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Oct 02

Sector Update: Healthcare

MT Newswires Live
·
Oct 02

Trump Medicare Drug Pricing Model May Apply to Only Four Companies After Exemptions

Reuters
·
Oct 02

Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says

MT Newswires Live
·
Oct 02

Eli Lilly (LLY) Ends Cancer Development Deal with Foghorn Therapeutics

TIPRANKS
·
Oct 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)

TIPRANKS
·
Oct 01

Foghorn Therapeutics Slashes Jobs After Ending Cancer Drug Trials with Ely Lilly

Dow Jones
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01